V-Go is an innovative, all-in-one insulin patch that’s proven to deliver effective outcomes by providing patients with a consistent and continuous basal rate as well as on-demand bolus.1-4
The right amount of insulin at the right time.
V-Go delivers basal-bolus when it’s needed.
Efficient Delivery for Better Glycemic Control
Significant and sustained A1c reduction in a broad range of patients with diabetes1
Patients with A1c>7.0% at baseline who were sub-optimally controlled on current diabetes therapy1
A1c reductions with V-Go were maintained through 6 months1
Study Design: In a retrospective analysis of an electronic medical records database, patients with uncontrolled diabetes (A1c>7.0%) on previous therapeutic regimens and switched to V-Go were Identified. A total of 153 patients were evaluated. Of these, 86 were on MDI, 45 on basal only, and 22 were insulin naive at baseline.1
Proven to Lower Insulin Requirements
The unique insulin delivery of V-Go significantly lowered basal-bolus requirements2
In patients who switched to V-Go from MDI, basal and bolus insulin requirements were reduced by 40% and 48%, respectively2
Patients who switched to V-Go from MDI had an average A1c reduction of 1.2% over 6 months
Study Design: Based on a real-world, retrospective analysis of an electronic medical records database. Patients were adults diagnosed with diabetes mellltus, A1c>7.0%, and previously prescribed basal-bolus Insulin therapy.2
V-Go Demonstrated Reductions in Glucose Variability
Optimized delivery with V-Go improved glycemic profiles and time in range5
In a 5-week, real-world study using the FreeStyle Libre Pro, patients using V-Go saw a 35% improvement in overall glucose time in range5
Overall glucose time below range decreased from 8.7% to 6.6%5
Study Design: A single-center, prospective, pilot study conducted using the FreeStyle Libre Pro in a real-world practice setting was designed to evaluate a percent change in blood glucose time in range (80-140 mg/dL) from baseline in patients switched from MDI to V-Go. Patients were on V-Go for a total of 5 weeks. Seven patients with type 2 diabetes and a stable dose of insulin, with a mean age of 64 years and weight of 226 lb, completed the pilot study.5
FreeStyle Libre Pro Is a registered trademark of Abbott Diabetes Care Inc.
Poster presented at the AACE 27th Annual Scientific and Clinical Congress, Boston, MA, May 2018.
References: 1. Lajara R, Nikkel C. Poster: Evaluating the effect of VGo therapy in suboptimally controlled patients with diabetes: a retrospective cohort analysis in a large specialized diabetes system. Presented at: AACE. May 2015. 2. Lajara R, Nikkel C. Poster: Evaluation of real world clinical and pharmacy budget outcomes when switching to a wearable insulin delivery device for insulin administration in patients with suboptimally controlled diabetes. Presented at: ISPOR. May 2017. 3. Sutton D, Higdon C, Nikkel C, Hilsinger K. Clinical benefits over time associated with use of V-Go Wearable Insulin Delivery Device in adult patients with diabetes: a retrospective analysis. Advances in Therapy 2018 May; 35(5): 631-43. 4. Instructions for Patient Use. P/N 2614-00 Rev. A 05/2019. 5. Parikh S, Dyson J, Nikkel C. Poster: 24 hour wearable basal bolus insulin delivery device improves time in range and treatment satisfaction over multiple daily injections a pilot study. Presented at: AACE. May 2018.
Important Risk Information
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.